Axsome Therapeutics Inc. (AXSM)
NASDAQ:AXSM
Want to see AXSM full AI Analyst Report?
Total Valuation
Axsome Therapeutics has a market cap or net worth of $11.70B. The enterprise value is $11.78B.
Market Cap$11.70B
Enterprise Value$11.78B
Share Statistics
Axsome Therapeutics has 51,459,766 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,459,766
Owned by Insiders15.38%
Owned by Institutions20.88%
Financial Efficiency
Axsome Therapeutics’s return on equity (ROE) is -2.07 and return on invested capital (ROIC) is -43.95%.
Return on Equity (ROE)-2.07
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-43.95%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee896.76K
Profits Per Employee-257.27K
Employee Count712
Asset Turnover0.93
Inventory Turnover1.70
Valuation Ratios
The current PE Ratio of Axsome Therapeutics is ―. Axsome Therapeutics’s PEG ratio is 1.29.
PE Ratio―
PS Ratio14.23
PB Ratio102.90
Price to Fair Value102.90
Price to FCF-96.78
Price to Operating Cash Flow-166.94
PEG Ratio1.29
Income Statement
In the last 12 months, Axsome Therapeutics had revenue of 638.50M and earned -183.17M in profits. Earnings per share was -3.68.
Revenue638.50M
Gross Profit591.02M
Operating Income-169.24M
Pretax Income-183.70M
Net Income-183.17M
EBITDA-168.08M
Earnings Per Share (EPS)-3.68
Cash Flow
In the last 12 months, operating cash flow was -70.73M and capital expenditures -263.00K, giving a free cash flow of -70.99M billion.
Operating Cash Flow-70.73M
Free Cash Flow-70.99M
Free Cash Flow per Share-1.38
Dividends & Yields
Axsome Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.81
52-Week Price Change118.06%
50-Day Moving Average185.59
200-Day Moving Average154.77
Relative Strength Index (RSI)68.27
Average Volume (3m)812.39K
Important Dates
Axsome Therapeutics upcoming earnings date is Aug 10, 2026, Before Open (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 10, 2026
Ex-Dividend Date―
Financial Position
Axsome Therapeutics as a current ratio of 1.55, with Debt / Equity ratio of 396.99%
Current Ratio1.55
Quick Ratio1.48
Debt to Market Cap0.02
Net Debt to EBITDA0.49
Interest Coverage Ratio-25.81
Taxes
In the past 12 months, Axsome Therapeutics has paid -530.00K in taxes.
Income Tax-530.00K
Effective Tax Rate<0.01
Enterprise Valuation
Axsome Therapeutics EV to EBITDA ratio is -53.57, with an EV/FCF ratio of -95.91.
EV to Sales14.10
EV to EBITDA-53.57
EV to Free Cash Flow-95.91
EV to Operating Cash Flow-96.40
Balance Sheet
Axsome Therapeutics has $305.11M in cash and marketable securities with $216.71M in debt, giving a net cash position of $88.40M billion.
Cash & Marketable Securities$305.11M
Total Debt$216.71M
Net Cash$88.40M
Net Cash Per Share$1.72
Tangible Book Value Per Share$0.72
Margins
Gross margin is 92.60%, with operating margin of -26.51%, and net profit margin of -28.69%.
Gross Margin92.60%
Operating Margin-26.51%
Pretax Margin-28.77%
Net Profit Margin-28.69%
EBITDA Margin-26.32%
EBIT Margin-27.74%
Analyst Forecast
The average price target for Axsome Therapeutics is $261.88, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$261.88
Price Target Upside38.57% Upside
Analyst ConsensusStrong Buy
Analyst Count19
Revenue Growth Forecast63.88%
EPS Growth Forecast35.18%